Exploring the next generation of antibody–drug conjugates
Jan 8, 2024 · Antibody–drug conjugates (ADCs) have emerged as a promising class of cancer therapeutics. An ADC consists of a monoclonal antibody and a potent cytotoxic payload connected through a...
Antibody drug conjugates make strides in ovarian cancer with …
Feb 12, 2024 · The UCLA Health women’s cancer research team in OBGYN played a pivotal role in a clinical trial that led to the FDA granting accelerated approval of the first antibody drug conjugate for the treatment of platinum-resistant ovarian cancer.
Billion-dollar bets on antibody–drug conjugates - Nature
Oct 22, 2024 · Last year was an outstanding period for deals focused on antibody–drug conjugates (ADCs), with Pfizer’s $43 billion acquisition of Seagen and AbbVie’s $10.1 billion buyout of ImmunoGen being...
Cancer-targeting antibody–drug conjugates drive dealmaking …
Feb 26, 2024 · Antibody–drug conjugates (ADCs) are driving a multi-billion-dollar dealmaking frenzy. Big pharma is snapping up ADC assets and technologies amid accelerating approvals, broadening indications...
Cancer-fighting antibodies inject chemo directly into tumor cells ...
Jun 2, 2024 · The chemotherapy-antibody combinations, known as antibody drug conjugates, have been described as both heat-seeking missiles and Trojan horses for cancer cells, designed to specifically...
Advancements in antibody-drug conjugates transform cancer …
Oct 22, 2024 · Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the...
Rise of Antibody-Drug Conjugates: The Present and Future
May 25, 2023 · Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells—so-called smart chemo.
Antibody-drug Conjugates - latest research news and features
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the...
Araris Biotech Publishes Foundational Science Behind its
2 days ago · Araris Biotech is a pioneering leader in the development of antibody-drug conjugates (ADCs) with the potential for unparalleled efficacy and tolerability. The Araris ADC technology AraLinQ ...
Antibody–drug conjugates: prospects for the next generation
1 day ago · To overcome chemotherapy toxicity, several approaches have been assessed, including the identification of drug delivery systems with a high local cytotoxic efficacy but with a lower systemic toxicity. 4 In the early 2000s, one of these novel approaches: antibody–drug conjugates (ADCs), consisted of joining one or more cytotoxic agent(s) onto a monoclonal antibody (mAb) via a linker, to ...